Results reported in the September issue of the Journal of Thoracic Oncology, the official journal of the International Association for the Study of Lung Cancer (IASLC), revealed the RET M918T ...

Novel oncogenic RET mutation found in small cell lung ... of SCLC as no other activating mutations were identified among the 19 oncogenes assayed in the tumor harboring the RET M918T mutation, ...

data on OS was only available for the RET‑M918T mutation-positive subgroup in EXAM (a specific type of RET mutation) the matching-adjusted treatment comparisons were not done in the relevant ...

CAMBRIDGE, Mass., April 15, 2018 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC), a leader in discovering and developing targeted kinase medicines for patients with genomically ...

Background: Medullary thyroid cancer (MTC) accounts for 1 to 2% of thyroid cancers in the United States; RET alterations occur in >95% of hereditary and 50% of sporadic forms. Up to 80% of patients ...

Somatic gain-of-function mutations in the RET ... of all MTC, which are sporadic. Depending on the method used and perhaps the region of origin, somatic RET mutations, predominantly M918T, ...

The RET functions by setting an annual income limit for those who have not yet reached full retirement age.If your earnings exceed this threshold, a portion of your monthly benefits will be ...

Already at 1.0 μ M, ZD6474 caused a complete morphological reversion of RET/C634R- and RET/M918T-transformed cells while it had very little effects on RET/V804M- and RET/V804L-transformed cells ...

A total 62.5% of patients had a RET M918T mutation. Additional efficacy findings showed that the PFS benefit with the highly selective, potent RET inhibitor was also observed via investigator ...

Background: Point mutations in RET tyrosine kinase, most commonly C634R and M918T, result in the development of medullary thyroid cancer (MTC). C634R and M918T occur in the cysteine-rich and kinase ...

Three patients previously treated with multi-kinase inhibitors had a RET M918T activating mutation and a RET V804M or V804L gatekeeper resistance mutation at baseline, and all three of these ...